Urol. praxi. 2017;18(2):50-53 | DOI: 10.36290/uro.2017.013

Comparison of therapy benign prostatic hyperplasia yesterday and today

MUDr. Slavomír Vachata, MUDr. Jiří Špaček, MUDr. Jaroslav Pacovský, Ph.D., doc. MUDr. Miloš Broďák, Ph.D.

Urologická klinika FN HK a LF UK Hradec Králové

The aim of study is evaluation of trends and changes in management of Benign Prostatic Hyperplasia (BPH)/Lower Urinary Tract

Symptoms (LUTS) in recent years. The main change is increasing number of patients on pharmacotherapy and declining surgeries

for this. The alfa1-lytics are very effective with rapid onset of effect and or very popular among urologist and patients. The 5alfa

inhibitors are the second main drugs. There are use very commonly in combination. We evaluated patients treated by pharmacotherapy

(n = 4 507) and patients after transurethral resections of prostate (TURP n = 451) and transvesical prostatectomy (TVPE n =

134) for 6 years (2010–2015). We compared numbers and results these cohorts. We found growth of pharmacotherapy is signifiant,

drop in surgical treatment of BPH/LUTS, slight increase the number of TVPE compared for the period 2003–2007.

Keywords: BPH – Benign Prostatic Hyperplasia, LUTS – Lower Urinary Tract Symptoms, alfa-lytics, 5alfa inhibitors, therapy

Published: May 1, 2017  Show citation